
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Recipient : Università degli Studi di Ferrara
Deal Size : Inapplicable
Deal Type : Inapplicable
Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC
Details : Salbutamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Insufficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 07, 2025
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Università degli Studi di Ferrara
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SF-RI 1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
Details : AeroFact (SF-RI 1) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : AeroFact
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 15, 2025
Lead Product(s) : SF-RI 1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Polarean
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Polarean
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observ...
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Nuance Pharma
Deal Size : $212.5 million
Deal Type : Licensing Agreement
Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...
Product Name : AeroFact
Product Type : Miscellaneous
Upfront Cash : $20.0 million
December 22, 2021
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Nuance Pharma
Deal Size : $212.5 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Undisclosed
December 09, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies
Details : Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system .
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 23, 2020
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epoprostenol Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
Details : Epoprostenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Epoprostenol Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SF-RI 1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
Details : SF-RI 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2019
Lead Product(s) : SF-RI 1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epoprostenol Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VentaProst (Epoprostenol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : VentaProst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2017
Lead Product(s) : Epoprostenol Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
